Brainomix 360 System for AI Imaging in Stroke Evaluated in Multiple Studies

February 19, 2025—Brainomix, a developer of artificial intelligence (AI) imaging solutions based in Oxford, United Kingdom, recently announced a series of new studies conducted with academic stroke institutions that validated the impact of its Brainomix 360 system to improve stroke treatment rates for patients across networks.

The studies were presented at the American Stroke Association’s International Stroke Conference 2025 (ISC) in Los Angeles, California.

According to the company, Brainomix 360 is a comprehensive, FDA-cleared platform powered by clinically validated AI algorithms built around basic imaging, most notably through the company’s flagship Brainomix e-ASPECTS module. The AI tool assesses noncontrast CT scans to automatically generate an ASPECTS score and features a heatmap that enables a nuanced assessment of each region.

In the United Kingdom, a real-world evaluation of stroke AI involved data from more than 71,000 patients across 26 National Health Service hospitals during a 3-year period. The findings showed that sites using Brainomix 360 doubled their thrombectomy rates during the evaluation period, increasing an additional 37% compared with nonevaluation sites, while also achieving a faster door-in-door-out time by 65 minutes, stated the company.

Kiruba Nagaratnam, MD, et al, presented the study in an oral abstract session at ISC.

Additionally, an evaluation in the United States of Brainomix 360 across the 17-site, multistate Mayo Clinic telestroke network included more than 900 stroke patients. The company stated that the results showed greater rates of thrombolysis as well as faster treatment decisions for both thrombolysis and thrombectomy when comparing the pre- and postimplementation phases.

As noted in the press release, the study investigators concluded, “This service evaluation highlighted the opportunity to improve efficiency of decision making even in the setting of a well-developed telestroke system. The impact was underpinned by the improved speed and confidence of imaging interpretation reflected in an offline simulation and qualitative feedback.”

Brett Smith, MD, et al, presented the United States study at ISC in a poster abstract session.

“We have had a longstanding academic partnership with Brainomix, harnessing their cutting-edge AI algorithms to explore some exciting scientific frontiers,” commented Waleed Brinjikji, MD, in the company’s press release. Dr. Brinjikji is Professor of Radiology & Neurosurgery at the Mayo Clinic in Rochester, Minnesota.

Dr. Brinjikji continued, “These latest studies have yielded fascinating insights around eloquence and brain frailty, revealing a more nuanced understanding of stroke, and informing potentially novel approaches to patient selection for stroke treatment.”